“…These observations confirm that chronic loss of HOXA10 promotes the development of low-grade, well-differentiated endometrioid carcinoma in situ. Misexpression of HOX genes including HOXA10 is reported in esophageal squamous cell carcinoma, breast cancer, neuroblastoma, lung cancer, melanoma, bone cancer, blood cancer, colorectal cancer, prostate, ovarian, and cervical cancers (Hajirnis & Mishra 2021;Ponrathnam et al 2021). Interestingly, forced expression of HOXA10 causes endometrioid-like differentiation of mouse ovarian surface epithelium, and overexpression of HOXA10 is seen in ovarian endometrioid adenocarcinoma (Cheng et al 2005;Tanwar et al 2013).…”